AlphAIalphai — Financial news for AI agents
marketscreener.comAUG 52 min read$UTHR

United Therapeutics: Q2 Earnings Snapshot

United Therapeutics (UTHR) reported Q2 net income of $333 million, or $7.27 per share, which beat Wall Street’s $6.82 estimate (Zacks). Revenue was $783.3 million, below the expected $803.5 million (Zacks).

Original reporting
marketscreener.com
Published Aug 5, 2026, 10:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 1:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$UTHR
Neutral
medium confidence
Mentioned
$UTHR
Relevance
7/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

$UTHRNeutralMed
01

Why it matters

Traders can reassess near-term expectations based on the EPS beat and revenue miss, but the article lacks guidance or operational drivers that typically drive larger repricing.

02

Market read

A straightforward earnings print with EPS upside versus consensus but revenue downside, setting a mixed fundamental tone for the next trading sessions.

03

What to watch

Without management guidance, segment/product performance, or cash flow details, the quality of the EPS beat (one-offs vs recurring) is unclear.

Relevance 7/10Novelty 6/10Timing: reported Q2 results on Wednesday

Background

AP-style earnings snapshot for United Therapeutics’ Q2 results versus Zacks consensus estimates.

Company-level read

Ticker impact

$UTHRNeutralMedium confidence
Context

United Therapeutics reported Q2 net income of $333 million and EPS of $7.27, beating analyst EPS expectations while revenue missed forecasts.

Expected impact

Near-term reaction likely muted to mixed unless management commentary (not provided here) clarifies revenue drivers and guidance.

Evidence & confidence

The article provides only headline financials versus consensus, with no guidance, product, or regulatory updates. EPS beat can support the stock, but revenue miss can cap upside.

Market effects

Sector

Signals continued earnings resilience for a biotech/pharma name despite revenue softness, but no broader sector read-through is provided.

Regional

No specific regional market linkage beyond company headquarters.

Global

No global macro or international regulatory/product developments mentioned.

Counterpoint

What could challenge this read

The revenue miss could indicate underlying demand or pricing pressure that EPS beat may not sustainably offset.

Key entities

  • company
    United Therapeutics Corp.

    Reported Q2 net income of $333 million, EPS of $7.27, and revenue of $783.3 million versus analyst expectations.

  • data_source
    Zacks Investment Research

    Provided the consensus estimates cited in the article for EPS and revenue.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 26
$UTHRHighAI 8/10

United Therapeutics (UTHR) Faces A Valuation Test After FDA Accepts Ralinepag NDA

United Therapeutics (UTHR) shares are under scrutiny after the FDA accepted its NDA for ralinepag, a treatment for pulmonary arterial hypertension, with a target action date set for June 24, 2027. The company's stock has seen a 1-year return of 67.69% and a 5-year return of 141.31%, but has dipped 9.15% in the past 90 days. Analysts suggest potential undervaluation, with a narrative fair value of $665.23 compared to the recent close of $518.53, citing its pipeline and long-term growth prospects.

simplywall.st2 min
AUG 24
$UTHRMedAI 9/10

FDA accepts United Therapeutics' ralinepag NDA for PAH

The FDA accepted United Therapeutics' NDA for ralinepag, a PAH treatment, with a PDUFA target date of June 24, 2027. The application is based on Phase III trial results showing a 55% reduction in clinical worsening events. If approved, ralinepag would be the first once-daily oral prostacyclin IP receptor agonist for PAH. The company also plans to develop a dry powder inhalation formulation with MannKind.

allsci.com2 min
AUG 15
$UTHRMedAI 8/10

United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript

United Therapeutics (NASDAQ: UTHR) reported Q2 2026 revenues of $783.3 million, down 2% year over year, and net income per diluted share of $7.27 versus $6.41. Tyvaso DPI sales were $326.6 million, while nebulized Tyvaso fell 18% to $126.0 million. Management discussed a path to a $4 billion 2027 revenue run rate amid competitive pressure and upcoming IPF and PAH launches.

aol.com6 min
AUG 5
$UTHRMed

UNITED THERAPEUTICS ($UTHR) Releases Q2 2026 Earnings

United Therapeutics (UTHR) reported Q2 2026 earnings of $7.27 per share, above the $6.97 estimate. Revenue was $783.3 million, below the $821.8 million estimate. The article also cites insider sales totaling 1,373 trades over six months, and notes a median analyst price target of $660.

quiverquant.com4 min